Multidisciplinary approach in management of patients with immune thrombocytopenia and ischemic heart disease
Yu. E. Ryabukhina,
A. A. Akhobekov,
A. M. Grigoryan,
P. A. Zeynalova,
M. M. Dombrovsky,
T. I. Kopaliani,
T. T. Valiev https://doi.org/10.17650/2782-3202-2025-5-1-59-65
Abstract
Immune thrombocytopenia in patients with concomitant cardiovascular disorders requiring antiplatelet and anticoagulant therapy can increase the risk of hemorrhages and arterial and venous thromboembolic complications. This situation necessitates special patient management. Multidisciplinary approach is important for patients requiring myocardial revascularization due to the necessity of administration of double or triple antiplatelet therapy.
The article presents our experience in management of patients with immune thrombocytopenia and high functional class stable angina requiring coronary artery stent.
About the Authors
Yu. E. Ryabukhina
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
Yulia Evgenyevna Ryabukhina
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
A. A. Akhobekov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
A. M. Grigoryan
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
P. A. Zeynalova
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies ; Department of Oncology, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
Bld. 2, 8 Trubetskaya St., Moscow 119991
M. M. Dombrovsky
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
T. I. Kopaliani
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
T. T. Valiev
Department of Oncology, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
Bld. 2, 8 Trubetskaya St., Moscow 119991
References
1. Matzdorff A., Meyer O., Ostermann H. et al. Immune Thrombocytopenia – current diagnostics and therapy: recommendations of a Joint Working Group of DGHO, ÖGHO, SGH, GPOH, and DGTI. Oncol Res Treat 2018;41(suppl 5):1–30 DOI: 10.1159/000492187
2. Idiopathic thrombocytopenic purpura (ITP) for adults. Clinical recommendations. 2021. (In Russ.). Available by: https://cr.minzdrav.gov.ru/schema/150_2
3. Provan D., Stasi R., Newland A.C. et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115(2):168–86. DOI: 10.1182/blood-2009-06-225565
4. Perera M., Garrido T. Advances in the pathophysiology of primary immune thrombocytopenia. Hematology 2017;22(1):41–53. DOI: 10.1080/10245332.2016.1219497
5. Audia S., Mahévas M., Samson M. et al. Pathogenesis of immune thrombocytopenia. Autoimmun Rev 2017;16(6):620–32. DOI: 10.1016/j.autrev.2017.04.012
6. Johnsen J. Pathogenesis in immune thrombocytopenia: new insights. Hematology Am Soc Hematol Educ Program 2012;2012:306–12. DOI: 10.1182/asheducation-2012.1.306
7. Cines D.B., Bussel J.B., Liebman H.A. et al. ITP syndrome: pathogenic and clinical diversity. Blood 2009;113(26):6511–21. DOI: 10.1182/blood-2009-01-129155
8. Sarpatwari A., Bennett D., Logie J.W. et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica 2010;95(7):1167–75. DOI: 10.3324/haematol.2009.018390
9. Doobaree I.U., Nandigam R., Bennett D. et al. Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. Eur J Haematol 2016;97(4):321–30. DOI: 10.1111/ejh.12777
10. Adelborg K., Kristensen N.R., Nørgaard M. et al. Cardiovascular and bleeding outcomes in a population-based cohort of patients with chronic immune thrombocytopenia. J Thromb Haemost 2019;17(6):912–24. DOI: 10.1111/jth.14446
11. Yakovlev A.N. Antiaggregants in cardiology: choice of best individual treatment. Meditsinskiy sovet = Medical Council 2015;(12):34-43. (In Russ.). DOI: 10.21518/2079-701X-2015-12-34-43
12. Knuuti J., Wijns W., Saraste A. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41(3):407–77. DOI: 10.1093/eurheartj/ehz425
13. Yusuf S., Zhao F., Mehta S.R. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345(7):494e502. DOI: 10.1056/NEJMoa010746
14. Vrints Ch., Andreotti F., Koskinas K.C. et al. ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J 2024;45(36):3415–537. DOI: 10.1093/eurheartj/ehae177
15. McCarthy C.P., Steg G., Bhatt D.L. The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum. Eur Heart J 2017;38(47):3488–92. DOI: 10.1093/eurheartj/ehx531
16. Lebowa W., Zdziarska J., Sacha T. Immune thrombocytopenia: characteristics of the population and treatment methods – one-center experience. Hamostaseologie 2023;43(2):132–41. DOI: 10.1055/a-1767-0304
17. Kuter D.J. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol 2013;98(1):10–23. DOI: 10.1007/s12185-013-1382-0
18. Vinogradova O.Yu., Pankrashkina M.M., Neverova A.L. et al. Primary immune thrombocytopenia and thrombopoietin receptoragonists: feasibilities of treatment discontinuation upon achieving stable complete platelet response. Klinicheskaya onkogematologiya = Clinical Oncohematology 2023;16(4):413–25. (In Russ.). DOI: 10.21320/2500–2139-2023-16-4-413-425
19. Ploume E.H., Wolcherink M.J.O., Buiten R.A. et al. Cost-effectiveness of three different new-generation drug-eluting stents in the randomised BIO-RESORT trial at 3 years. Pharmacoecon Open 2025;9(1):137–45. DOI: 10.1007/s41669-024-00539-x
20. Navarese E.P., Kowalewski M., Kandzari D. et al. First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients. Open Heart 2014;1:e000064. DOI: 10.1136/openhrt-2014-000064
Review
For citations:
Ryabukhina Yu.E., Akhobekov A.A., Grigoryan A.M., Zeynalova P.A., Dombrovsky M.M., Kopaliani T.I., Valiev T.T. Multidisciplinary approach in management of patients with immune thrombocytopenia and ischemic heart disease. MD-Onco. 2025;5(1):59-65. (In Russ.) https://doi.org/10.17650/2782-3202-2025-5-1-59-65
Views:
84
Email this article 